IGFBP7 (Insulin-Like Growth Factor–Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure
暂无分享,去创建一个
S. Solomon | J. McMurray | A. Shah | M. Zile | B. Pieske | A. Voors | M. Packer | B. Claggett | M. Lefkowitz | V. Shi | J. Januzzi | M. Prescott | Jiankang Liu | P. Gandhi
[1] Y. Goshima,et al. Reduction and fragmentation of elastic fibers in the skin of obese mice is associated with altered mRNA expression levels of fibrillin-1 and neprilysin , 2017, Connective tissue research.
[2] Biao Xu,et al. Premature senescence of cardiac fibroblasts and atrial fibrosis in patients with atrial fibrillation , 2017, Oncotarget.
[3] Akshay S. Desai,et al. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. , 2017, JACC. Heart failure.
[4] C. Vrints,et al. Endothelial Senescence Contributes to Heart Failure With Preserved Ejection Fraction in an Aging Mouse Model , 2017, Circulation. Heart failure.
[5] R. Kim,et al. Redefining the role of biomarkers in heart failure trials: expert consensus document , 2017, Heart Failure Reviews.
[6] Y. Koh,et al. Neprilysin facilitates adipogenesis through potentiation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway , 2017, Molecular and Cellular Biochemistry.
[7] R. McKelvie,et al. Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. , 2017, Journal of cardiac failure.
[8] Patrizio Lancellotti,et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2016, European heart journal cardiovascular Imaging.
[9] K. Anstrom,et al. Insulin-Like Growth Factor-Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity in Heart Failure With Preserved Ejection Fraction: Results From the RELAX Trial. , 2016, JACC. Heart failure.
[10] M. Konstam,et al. Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials , 2016, Circulation. Heart failure.
[11] Patrizio Lancellotti,et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2016, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[12] S. Solomon,et al. Left Atrial Structure and Function Across the Spectrum of Cardiovascular Risk in the Elderly: The Atherosclerosis Risk in Communities Study , 2016, Circulation. Cardiovascular imaging.
[13] J. Kellum,et al. Cell-cycle arrest and acute kidney injury: the light and the dark sides , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[14] S. Solomon,et al. Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection FractionCLINICAL PERSPECTIVE , 2016 .
[15] S. Solomon,et al. Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. , 2016, Circulation. Heart failure.
[16] A. Sheftel,et al. Prognostic usefulness of insulin-like growth factor-binding protein 7 in heart failure with reduced ejection fraction: a novel biomarker of myocardial diastolic function? , 2014, The American journal of cardiology.
[17] S. Solomon,et al. Elevation in High-Sensitivity Troponin T in Heart Failure and Preserved Ejection Fraction and Influence of Treatment With the Angiotensin Receptor Neprilysin Inhibitor LCZ696 , 2014, Circulation. Heart failure.
[18] Richard T. Lee,et al. Heart failure with preserved ejection fraction: molecular pathways of the aging myocardium. , 2014, Circulation research.
[19] Milton Packer,et al. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. , 2014, Journal of the American College of Cardiology.
[20] A. Chambery,et al. Insulin-like growth factor binding proteins 4 and 7 released by senescent cells promote premature senescence in mesenchymal stem cells , 2013, Cell Death and Disease.
[21] A. Gramolini,et al. Pilot study identifying myosin heavy chain 7, desmin, insulin‐like growth factor 7, and annexin A2 as circulating biomarkers of human heart failure , 2013, Proteomics.
[22] E. Hara,et al. Roles and mechanisms of cellular senescence in regulation of tissue homeostasis , 2013, Cancer science.
[23] Azra Bihorac,et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury , 2013, Critical Care.
[24] S. Solomon,et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial , 2012, The Lancet.
[25] M. Maurer,et al. Heart failure with a preserved ejection fraction: what is in a name? , 2011, Journal of the American College of Cardiology.
[26] A. Balmforth,et al. Neprilysin, obesity and the metabolic syndrome , 2010, International Journal of Obesity.
[27] Y. Takema,et al. Neprilysin Is Identical to Skin Fibroblast Elastase , 2010, The Journal of Biological Chemistry.
[28] D. Kass,et al. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. , 2007, Journal of the American College of Cardiology.
[29] J. Fernández-Real,et al. Insulin Resistance Is Associated With Increased Serum Concentration of IGF-Binding Protein–Related Protein 1 (IGFBP-rP1/MAC25) , 2006, Diabetes.
[30] J. Cuzick,et al. A Wilcoxon-type test for trend. , 1985, Statistics in medicine.